Abstract
A real revolution is under way in the development of medicinal preparations. New-generation medicines are able to change the course of oncological and cardiovascular diseases, as well as type one and type two diabetes mellitus. So-called “small molecules” are used to affect biological processes and monoclonal antibodies, which are valuable tools to control cells that cause pathological processes. Target preparations are able to identify damaged cells and destroy exclusively malignant neoplasms, not affecting healthy organs and tissues. Individually selected drug-induced therapy contributes to quick improvement in the patient’s condition and reduces considerably the risk of lethal outcome.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © A.G. Chuchalin, 2016, published in Vestnik Rossiiskoi Akademii Nauk, 2016, Vol. 86, No. 6, pp. 480–483.
RAS Academician Aleksandr Grigor’evich Chuchalin is director of the Research Institute of Pulmonology, Federal Medical and Biological Agency of Russia.
Rights and permissions
About this article
Cite this article
Chuchalin, A.G. Innovative drugs of the 21st century. Her. Russ. Acad. Sci. 86, 143–146 (2016). https://doi.org/10.1134/S1019331616030060
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1019331616030060